Polaris Venture Management Co. V, L.L.C. - Q1 2018 holdings

$175 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 11 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 10.0% .

 Value Shares↓ Weighting
ASNS  Arsanis, Inc.$42,780,000
+79.4%
1,868,9570.0%24.39%
+16.0%
CDLX NewCardlytics, Inc.$38,569,0002,636,262
+100.0%
21.99%
KALA  Kala Pharmaceuticals, Inc.$29,406,000
-14.4%
1,857,5820.0%16.76%
-44.6%
FATE  Fate Therapeutics, Inc.$24,138,000
+59.7%
2,473,1860.0%13.76%
+3.3%
SELB  Selecta Biosciences, Inc.$16,373,000
+3.9%
1,606,8130.0%9.33%
-32.8%
TTOO  T2 Biosystems, Inc.$12,172,000
+57.5%
1,875,5240.0%6.94%
+1.8%
LIFE  Atyr Pharma Inc.$4,844,000
-24.3%
1,827,9920.0%2.76%
-51.1%
TRVN  Trevena, Inc.$3,368,000
+2.5%
2,053,5400.0%1.92%
-33.7%
GNCA  Genocea Biosciences, Inc.$2,067,000
-9.5%
1,968,6060.0%1.18%
-41.5%
PULM  Pulmatrix, Inc.$1,423,000
-63.9%
2,796,4070.0%0.81%
-76.7%
DARE  Dare Bioscience, Inc.$273,000
-61.3%
326,2430.0%0.16%
-75.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-05-04
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Fate Therapeutics, Inc.30Q2 202179.2%
Atyr Pharma Inc.26Q3 202115.1%
Trevena, Inc.22Q2 201924.9%
Genocea Biosciences, Inc.21Q1 201932.5%
Selecta Biosciences, Inc.20Q1 202139.5%
T2 Biosystems, Inc.20Q2 201936.1%
Dare Bioscience, Inc.17Q3 20213.9%
Pulmatrix, Inc.16Q1 201915.4%
Cerulean Pharma Inc13Q2 201716.2%
Kala Pharmaceuticals, Inc.11Q1 202037.1%

View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.

Latest filings
TypeFiled
32022-03-30
13F-HR2021-11-12
13F-HR2021-08-12
13F-HR2021-05-12
13F-HR2021-02-12
13F-HR2020-11-12
13F-HR2020-08-12
13F-HR2020-05-14
42020-05-06
32020-04-30

View Polaris Venture Management Co. V, L.L.C.'s complete filings history.

Compare quarters

Export Polaris Venture Management Co. V, L.L.C.'s holdings